Entera and Opko report PK data for oral GLP-2 peptide tablet for short bowel syndrome
March 21, 2024
Entera Bio Ltd. has announced promising pharmacokinetic (PK) results from its collaborative research combining a proprietary long-acting GLP-2 agonist developed by Opko Health Inc. with Entera’s proprietary N-Tab technology.
